Chiisanoside is the main component of Acanthopanax sessiliflorus leaves. Simultaneous administration of chiisanoside resulted in a decrease in the plasma TG level and increase of undigested TG in the intestinal lumen after oil gavage to mice. This suggests that chiisanoside has the potential to prevent obesity as a lipase inhibitor which suppresses fat absorption in vivo.
'Wu jia' is a famous Chinese folk medicine, and several araliaceous plants have been used as its source. Acanthopanax sessiliflorus is also one of the source plants of this folk medicine, which is mainly grown in China and Korea, and root bark have traditionally used it for a tonic or sedative drug, as well as for the treatment of rheumatism and diabetes. 1) Chiisanoside, 1-hydroxy-3, 4-seco-4 (23), 20 (29)-lupadien-3, 11-olid-28-oic acid 28-O--L-rhamnopyranosyl (1!4)--D-glucopyranosyl (1!6)--D-glucopyranoside, is the main component of A. sessiliflorus leaves. In our previous study, 2) we have reported that chiisanoside inhibited pancreatic lipase activity in a dose-dependent manner in vitro. Furthermore, the addition of the saponin-rich fraction (SF) of A. sessiliflorus containing chiisanoside at 42.6% (w/w) was shown to suppress the increase of body weight gain in mice when added to a high-fat diet for 4 weeks of feeding.
2) It has been reported that tea catechins exerted an anti-obesity action on experimental animals and humans. Catechins are known to not only suppress lipid absorption by inhibiting pancreatic lipase activity in the digestive tract, 3, 4) but also to burn fat by the activation of -oxidation in the liver. 5, 6) Saponins have been reported as lipase inhibitors and many of them have been proved to reduce the body weight of experimental animals. 2, [7] [8] [9] [10] [11] However, little evidence has been obtained on the intestinal absorption of saponins and their involvement in hepatic fatty acid metabolism after intestinal absorption. The purpose of this study is to elucidate the antiobesity mechanism of chiisanoside from the possibility of its absorption.
Chiisanoside was prepared and purified as reported previously.
2) Male ddY mice (4 weeks old) were purchased from Japan SLC (Hamamatsu, Japan). The animal care and experimental procedures were approved by the Committee for Animal Experimentation of Faculty of Medicine, The University of Tokushima and by the Committee of Animal Care and Experiments of University of Toyama. Measurement of the plasma triacylglycerol (TG) level after the oral administration of 5 ml/kg of safflower oil to the mice was performed as previously described. 12) In order to know the effect of chiisanoside on the oil absorption, the plasma and contents of the small intestine and cecum were obtained 4 h after oral administration of triolein with or without chiisanoside. The small intestinal and cecal contents were divided into two aliquots. One was added to the same volume of MeOH to extract the chiisanoside. The other was added to the same volume of CH 3 Cl/MeOH (2:1, v/v) to extract the total lipids according to the method of Bligh and Dyer. 13) Both extracts were centrifuged at 10;000 Â g for 10 min to obtain the supernatant. The TG concentration in the CH 3 Cl/MeOH extract was measured by high-performance thin-layer chromatography (HPTLC; silica gel 60 plates, Merck, Germany), and an aliquot of the total lipids was applied to the plate by using a Linomat 5 semi-automatic applicator (Camag, Muttenz, Switzerland). The plate was developed with a mixture of hexane/isopropanol/ acetic acid (90:10:1, v/v). The spots of the total lipids were visualized with iodine. The chiisanoside content was measured by HPLC with a columun of Capcell Pak C 18 (UG-120, 4.6 mm I.D. Â 150 mm; Shiseido, Tokyo, Japan). The mobile phase was a 35% (v/v) acetonitrile solution containing 0.1% (v/v) trifluoroacetic acid at a flow rate of 1.0 ml/min at 40 C. Elution was detected by a CoronaÔ charged aerosol detector (CAD; ESA Biosciences, Chelmsford, MA, USA) operated with nitrogen as the nebulizing gas in a range of 500 pA. The plasma and MeOH extracts were applied to a Sep-Pak C 18 cartridge and eluted with MeOH. The eluate was evaporated to dryness, and the residue was dissolved in the mobile phase and then injected into the column.
Chiisanoside, belonging to the family of 3, 4-secolupane-type triterpenoid saponins, is the major component of A. sessiliflorus leaves, and has also been isolated from A. chiisanensis, 14) A. divaricatus 15) and A. senticosus. 16) In this study, the effect of chiisanoside on the elevation of the plasma TG level after oil gavage was examined in mice. The plasma TG level was increased 2 and 4 h after oral administration of the oil, this being followed by a decrease 6 h after the administration. The addition of 100 or 300 mg/kg of chiisanoside to the oil significantly suppressed the elevation of plasma TG level for 6 h after oil gavage (p < 0:05), its effect being the strongest at 4 h after dosage (Fig. 1A) . When the change in plasma TG level is expressed as the area under the concentration-time curve (AUC), the TG level was significantly suppressed by the addition of chiisanoside (p < 0:05) as compared with the control group (Fig. 1B) . We have previously reported that chiisanoside inhibited the pancreatic lipase activity in vitro.
2) The lipid contents in the small intestine and the cecum 4 h after the oral administration of 100 ml of oil, 100 mg/kg of chiisanoside or oil plus chiisanoside to the mice were examined by an HPTLC analysis. As shown in Fig. 2 , the amounts of TG remaining in the small intestine and cecum were greater in the mice administered with oil and chiisanoside (n ¼ 3) than in those with oil but without chiisanoside (n ¼ 3). These results indicate that chiisanoside suppressed the small intestinal absorption of dietary fat by inhibiting the pancreatic lipase activity in vivo. An HPLC analysis showed that the recovery of chiisanoside from the intestinal and cecal contents was 76:52 AE 45:10% and 71:52 AE 37:43% of the dose in the 100 mg/kg of chiisanoside without and with oil group, respectively. This HPLC analysis was then adopted to determine the plasma concentration of chiisanoside. The retention time of standard chiisanoside was 9.14 min, Safflower oil (5 ml/kg) with or without chiisanoside was orally administrated to mice, and blood was obtained 0, 2, 4 and 6 h after oil gavage. A, Triacylglycerol (TG) level and B, area under the concentration-time curve (AUC). Symbols: control (oil alone) group ( ), high (oil plus 300 mg/kg of chiisanoside) group ( ), and low (oil plus 100 mg/kg of chiisanoside) group ( ). Data are presented as the mean AE SD (n ¼ 6). Data were analyzed by one-way ANOVA, and differences among means were then analyzed by using Fisher's PLSD test. Ã Differences were considered to be significant from the control group (p < 0:05). and the peak was free from interference by endogenous substances in the plasma (Fig. 3) . The slope of the calibration curve of chiisanosides had a correlation of 0.998 in the range of 0.05-2 mg/ml. Under these conditions, the detection limit was 95.5 ng/ml (data not shown here). Chiisanoside was under the detection limit (95.5 ng/ml = 0.1 mmol/l) in the mouse plasma when chiisanoside administration (100 mg/kg) significantly reduced the plasma TG level as shown in Fig. 1  (Fig. 3D) . When the rats were used for investigating the chiisanoside absorbability to increase the analytical sensitivity, chiisanoside was not detected in the plasma at any time during 6 hrs after its 100 mg/kg administration (data not shown). It is known that the efficiency of intestinal absorption for epigallocatechin gallate (EGCG), the main component of tea catechins, is relatively low. Lambert et al. have reported that, after the administration of EGCG intragastrically at 163.8 mmol/kg (75 mg/kg) to mice, its peak plasma level was 0:28 AE 0:08 mmol/l (0:13 AE 0:04 mg/ml). These results support the notion that chiisanoside is hardly absorbed, and does not show apparent toxicity.
In conclusion, chiisanoside suppressed lipid absorption in the intestinal tract by inhibiting pancreatic lipase activity. On the other hand, no chiisanoside was detected in the plasma, indicating that it is unlikely to consume fats by stimulating -oxidation in the liver. These results strongly support these in our previous report 2) that chiisanoside is the major physiologicaly functional component of the saponin-rich fraction of A. sessiliflorus and might be a novel dietary anti-obesity compound possessing a lipase-inhibiting effect in vivo with high safety. A, standard chiisanoside (0.5 mg/ml); B, blank mouse plasma; C, blank mouse plasma spiked with chiisanoside (1 mg/ml); D, plasma sample from the mouse 4 h after oral administration of chiisanoside (100 mg/kg).
